SCHEMBL2804753

SCHEMBL2804753

CN(CC(=O)O)C(=O)CCCCCCCCC(=O)N(C)CC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.46
KDM4A O75164 11/20 0.46
KDM4C Q9H3R0 11/20 0.46
KDM5A P29375 1/20 0.46
KDM7A Q6ZMT4 1/20 0.46
PHF8 Q9UPP1 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
TSHR P16473 2/20 0.43
LMNA P02545 1/20 0.43
NFKB1 P19838 1/20 0.43
PMP22 Q01453 1/20 0.43
MVD P53602 1/20 0.42
GPR84 Q9NQS5 2/20 0.41
PPARG P37231 2/20 0.41
PPARD Q03181 2/20 0.41
PPARA Q07869 2/20 0.41
ALDH1A1 P00352 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
TLR2 O60603 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL597177 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR
SCHEMBL3997562 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR
SCHEMBL4396598 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR
SCHEMBL2904687 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR
SCHEMBL1116228 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR
SCHEMBL25183153 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR
SCHEMBL8776565 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR
SCHEMBL219261 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR
SCHEMBL2852602 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR
SCHEMBL597683 0.92 EPHX2 (0.57) EPHX2KDM4CKDM5APHF8TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249360-B2 Compositions derived from metathesized natural oils and amines and methods of making ELEVANCE RENEWABLE SCIENCES, INC. (US) 2016-02-02 US claimed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
EP-2207525-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'Oréal (FR) 2010-07-21 EP claimed
EP-2205201-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'Oreal (FR) 2010-07-14 EP claimed
WO-2009053594-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO claimed
WO-2009053587-A2 COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO claimed
WO-2009053584-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO claimed
EP-1455774-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY LEAN EX LTD (IL) 2006-03-01 EP claimed
EP-0637958-B1 ANTI-OBESITY DRUGS SENYORINA LTD (IL) 1997-04-02 EP claimed
EP-2207525-B1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'ORÉAL (FR) 2017-02-22 EP disclosed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
WO-2009053594-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO disclosed
WO-2009053587-A2 COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO disclosed
WO-2009053584-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed
EP-2008647-A1 Cosmetic or pharmaceutical composition comprising a condensation polymer, cosmetic treatment method, condensation polymer and preparation method L'Oreal (FR) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 EPHX2 301/4885KDM4A 2848/4885KDM4C 1878/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB EPHX2 3893/4885KDM4A 2509/4885KDM4C 1357/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA EPHX2 771/4885KDM4A 1764/4885KDM4C 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.